Skip to main content
Fig. 2 | Experimental Hematology & Oncology

Fig. 2

From: Cyclin dependent kinase 4/6 inhibitor palbociclib synergizes with BCL2 inhibitor venetoclax in experimental models of mantle cell lymphoma without RB1 deletion

Fig. 2

Effect of palbociclib on clones with overexpression of MYC, CDK4, CDKN2A and K/O of CDKN2A and RB. Legend: the figure shows relative comparison of half-maximal inhibitory concentration (IC50, in nM) in response to palbociclib between MCL clones (IC50clone) and corresponding controls (IC50CTRL). The bars were constructed according to the following formulas: 1 + IC50CTRL / IC50clone in the cases when IC50clone > IC50CTRL; 1 - IC50clone / IC50CTRL in the cases when IC50CTRL > IC50clone. Positive and negative bars represent more sensitive and resistant clones, respectively (compared to controls)

Back to article page